Safety and Tolerability of SYNB1020-CP-001
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Volunteer, Urea Cycle Disorder
In brief
A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate Safety, Tolerability, Dosing, and Pharmacodynamics
Key facts
- Study ID
- NCT03179878
- Run by
- Synlogic
- People needed
- 52
- Starts
- 2017-06-16
- Expected to finish
- 2018-04-11
- Last updated by the study team
- 2021-05-12
Who can join
Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.
Where it is running
- Parexel — Brooklyn, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.